Biochemical and Kinetic Studies on Alkaline Phosphatase and other Biochemical Features in Sera of Patients with type 2 Diabetes

Background :Alkaline phosphatase (ALP) was a widely used marker for skeletal and hepatobiliary disorders, but its activity was also increased in atherosclerosis and peripheral vascular disease. Several study has showed that ALP activity was increased in the sera of diabetic patients. The current study was conducted to evaluate ALP activity in type 2 diabetic patients and optimum conditions for enzyme activity in their sera.Methods: This study was carried out at in AL-Yarmok hospital(diabetic center) between February /2009 and April /2009. Fifty two patients with type 2 diabetes have been enrolled. Besides BMI, WHR, serum fasting blood glucose, ALP, HbA1C,uric acid and lipid profile levels have been performed .The relationship between ALP and other biochemical factors have been studied.Results: From a total 52 cases, FBG, HbA1C and ALP were significantly elevated P value < 0.01 while Uric acid, Cholesterol, TG, HDL, LDL,VLDL and LDL/HDL were significantly different P value < 0.05 in diabetic patients when compared with that found in control group . ALP was significantly associated with LDL (P < 0.05) and significantly negative correlation with HbA1C (

Evaluation of Asprosin Hormone in Hypothyroidism Patients

Asprosin was a novel adipokine that was released by white adipose tissue. It was activated by fasting and attracted to the liver, which allowed the liver to rapidly release glucose into the bloodstream. White adipose tissue was the source of asprosin. When people go on a fast, their blood sugar levels drop, which causes levels of the hormone asprosin to rise. It does this by binding to a G-protein-coupled receptor in the liver known as OR4M1, which in turn activates a cascade that involves the G -protein-cAMP-PKA pathway. Because of this, the glucose that is stored in the liver is released.  We anticipate that by investigating the changes that occur in asprosin levels in hypothyroidism patients, we will be able to make a significant addition to the area and fill a gap that has been left unexplored in the anther researches. Eighty patients (women ) ranging in age from 25 to 65 were collected from the National Diabetes Center Al-Mustansiriyah University (Iraq) for the purpose of this study, which was designed as a cross-sectional study to determine the concentrations of serum ( asprosin, thyroid hormone T3 T4 TSH, Fasting blood glucose FBG, and lipid profile( Total cholesterol TCho,Triglycride TG,high density lipoprotein HDL, Low density lipoprotein LDL, Very low density lipoprotein VLDL) . In the period beginning in December 2021 and continuing until March 2022. This particular study included a total of 80 participants, 40 of whom had thyroid disease (hypothyroidism), and 40 healthy individuals who served as controls. When compared to the control group, the findings of this study indicate that    the levels of total cholesterol TC, triglycerideTG, and low-density lipoprotein (LDL) have dramatically increased, whilst the levels of HDL have significantly decreased . A substantial increase in  (Fasting blood glucose FBG and Body mass index BMI) levels was also observed, in contrast to the group that served as the control. In patients with hypothyroidism, the levels of thyroid-stimulating hormone TSH were considerably greater, while the levels of  T3 were significantly lower. The T4 level, however, revealed no significant differences when compared to the control group. In addition, the level of asprosin was found to be high in the hypothyroidism group only contrast  to the control group that participated in this research.  This current study indicates the hormone asprosin could be helpful early diagnosis in monitoring hypothyroidism patients. hormone asprosin is a marker of glucose homeostasis, so it may be surrogate novel biomarker for all other traditional biomarkers for the prediction of risk factors of diabetes and thyroid dysfunctio

Serum Interleukin-6 level in children with type 1 diabetes mellitus

pancreatic islets in which a process of programmed cell death (apoptosis) is elicited in the β-cells by interaction of activated T-cells and proinflammatory cytokines in the immune infiltrate. Interleukin-6 (IL-6) is a pleiotropic cytokine with a key impact on both immunoregulation and nonimmune events in many cell types . Objective: to assess the level of serum IL-6 as an inflammatory marker in type 1 diabetic children, with correlation to FBG and HbA1c. Subjects and methods: 45 type 1 diabetic child (20 males and 25 females), mean age 10.9± 3.4 years who attended the National Diabetic Center, Al-Mustansiria university were included in this study. 45 apparently healthy controls matched for age and sex were participated in this study .Fasting venous blood samples were collected from all the subjects. The serum was used for analyzing HbA1c, Fasting Blood Glucose (FBG) and IL-6, HbA1c was estimated by high performance liquid chromatography ,Serum glucose level was determined enzymatically and serum IL-6 was measured by enzyme linked immune sorbent assay.Analysis of data was performed using the statistically package for social science (SPSS) version 17.0. Results: Mean serum IL-6 level in type 1 diabetic children were significantly higher compared to the healthy controls (30.9 Pg/ml ±10.85versus 10.57 Pg/ml±1.98 (P ≤0.0001), and positive strong correlation was found between serum IL-6 and FBS, HbA1C ,BMI. Conclusion: There is a low-level of chronic inflammatory state in type 1 diabetic children reflected by the level of serum IL-6, that may play a key role in the early stages of atherogenesis and the development of microvascular complications

Ghrelin Levels in Male Patients with Hyperlipoproteinemia I, II versus Type 2 Diabetes Mellitus.

Background; Hyperlipoproteinemia (HLP)  are divided in primary and secondary subtypes. Primary HLP is usually due to genetic causes. Secondary HLP is resulting from another underlying disorder such as diabetes mellitus that leads to alterations in plasma lipid and lipoprotein metabolism, HLP may be idiopathic . Patients and Methods; Ninety male individuals (age 30-45)years were enrolled in this study which were divided into three groups as follows:- (G1) consist of 30 healthy male individuals as a control group, (G2) consist of  30 male patients with (HLP) without any other disease  (15 of them were HLP1,the other were HLP11), (G3) consist of 30 male patients with DM2 without any other disease .(Ghr),  fasting blood glucose (FBG), c-peptide, Insulin, Insulinresistance (IR), Insulin sensitivity (S%),  Beta cell function(B%) ,Glucose/ Insulin ratio, triacylglycerol(TG),total cholesterol (TC), low density lipoprotein(LDL),high density lipoprotein(HDL),very low density lipoprotein(VLDL),TC/HDL ratio, LDL/HDL ratio and atherogenic index of plasma(AIP) were evaluated .Objectives; The aims of this paper were to evaluate the differences in the  ghrelin hormone (Ghr) levels between healthy control and patients with primary hyperlipoproteinemia  [hyperlipoproteinemia I (HPLI) , hyperlipoproteinemia II (HPLII)]  and secondary hyperlipoproteinemia [ type 2 diabetes mellitus(DM2)], and  study the relation of (Ghr) with other parameters. Results; The mean level of Ghr was significantly lower (P<0.05) in DM2 compared with control group, significantly higher(P<0.05) in HLP1 compared with HLP11 and DM2 and significantly higher(P<0.05) in HLPII compared with DM2. There were  significant correlations between Ghr level and (insulin, c-peptide ,IR,S% ,TG ,VLDL ,AIP) in patients with DM2 and  significant correlations between Ghr level and (TG ,LDL ,VLDL ,LDL/HDL ratio ,c-peptide ,S%)in patients with HLPI. Conclusion; We conclude that low plasma Ghr level is closely related to atherogenicity in DM 2 patients while there is no significant relationship between them in HLPI and HLPII